Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor

Immune checkpoint inhibitors (ICIs) have revolutionized medical practice in oncology since the FDA approval of the first ICI 11 years ago. In light of this, Lymphocyte-Activation Gene 3 (LAG-3) is one of the most important next-generation immune checkpoint molecules, playing a similar role as Progra...

Descripción completa

Detalles Bibliográficos
Autores principales: Chocarro, Luisa, Bocanegra, Ana, Blanco, Ester, Fernández-Rubio, Leticia, Arasanz, Hugo, Echaide, Miriam, Garnica, Maider, Ramos, Pablo, Piñeiro-Hermida, Sergio, Vera, Ruth, Escors, David, Kochan, Grazyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367598/
https://www.ncbi.nlm.nih.gov/pubmed/35954196
http://dx.doi.org/10.3390/cells11152351

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9367598/
https://www.ncbi.nlm.nih.gov/pubmed/35954196
http://dx.doi.org/10.3390/cells11152351

Ejemplares similares